These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 17897678

  • 1. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
    De Stefano N, Filippi M, Hawkins C, 9011 study group.
    J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
    [Abstract] [Full Text] [Related]

  • 2. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.
    Mult Scler; 2008 Jun 15; 14(5):663-70. PubMed ID: 18424479
    [Abstract] [Full Text] [Related]

  • 3. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 15; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 4. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.
    BMC Neurol; 2006 May 23; 6():19. PubMed ID: 16719908
    [Abstract] [Full Text] [Related]

  • 5. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 23; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 6. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
    Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
    [Abstract] [Full Text] [Related]

  • 7. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
    Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
    Mult Scler; 2008 Apr 10; 14(3):370-82. PubMed ID: 18208877
    [Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
    Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
    [Abstract] [Full Text] [Related]

  • 9. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators.
    Mult Scler; 2009 Oct 20; 15(10):1183-94. PubMed ID: 19776092
    [Abstract] [Full Text] [Related]

  • 10. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G.
    J Neurol Sci; 2008 Apr 15; 267(1-2):28-35. PubMed ID: 17945260
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 15; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

  • 12. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Miller A, Spada V, Beerkircher D, Kreitman RR.
    Mult Scler; 2008 May 15; 14(4):494-9. PubMed ID: 18208875
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
    Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E, Weiss S, Shifroni G, Wolinsky JS, Filippi M, European/Canadian Glatiramer Acetate Study Group.
    Mult Scler; 2007 May 15; 13(4):502-8. PubMed ID: 17483532
    [Abstract] [Full Text] [Related]

  • 14. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 15; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 15. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 15; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 16. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
    Clin Ther; 2010 Jun 15; 32(6):1061-6. PubMed ID: 20637960
    [Abstract] [Full Text] [Related]

  • 17. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
    Zivadinov R, Bagnato F, Nasuelli D, Bastianello S, Bratina A, Locatelli L, Watts K, Finamore L, Grop A, Dwyer M, Catalan M, Clemenzi A, Millefiorini E, Bakshi R, Zorzon M.
    J Neurol Sci; 2004 Aug 30; 223(2):185-93. PubMed ID: 15337621
    [Abstract] [Full Text] [Related]

  • 18. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y, Traboulsee A, Petkau AJ, Li D.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
    Arch Neurol; 2005 Dec 25; 62(12):1843-7. PubMed ID: 16344342
    [Abstract] [Full Text] [Related]

  • 20. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
    Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T.
    J Neurol; 2008 Oct 25; 255(10):1473-8. PubMed ID: 18854910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.